Given the high zinc-binding capacity of S100A6, we proposed that the elevated expression of S100A6 around amyloid plaques in patients with AD might play an important role in inhibiting Aβ aggregation and plaque formation through competition for zinc. The gene discussed is S100A6; the disease is amyloidosis.